Assuntos
Neoplasias da Mama , Injeções Espinhais , Neoplasias Meníngeas , Metotrexato , Tiotepa , Humanos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Feminino , Metotrexato/administração & dosagem , Tiotepa/administração & dosagem , Neoplasias Meníngeas/secundário , Neoplasias Meníngeas/tratamento farmacológico , Carcinomatose Meníngea/tratamento farmacológico , Carcinomatose Meníngea/secundárioAssuntos
Antineoplásicos Hormonais , Densidade Óssea , Neoplasias da Mama , Pré-Menopausa , Tamoxifeno , Humanos , Tamoxifeno/efeitos adversos , Tamoxifeno/uso terapêutico , Feminino , Neoplasias da Mama/tratamento farmacológico , Densidade Óssea/efeitos dos fármacos , Antineoplásicos Hormonais/efeitos adversos , Antineoplásicos Hormonais/uso terapêuticoAssuntos
Antimetabólitos Antineoplásicos , Neoplasias da Mama , Capecitabina , Receptor ErbB-2 , Receptores de Estrogênio , Receptores de Progesterona , Humanos , Capecitabina/uso terapêutico , Capecitabina/administração & dosagem , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Neoplasias da Mama/metabolismo , Feminino , Receptor ErbB-2/metabolismo , Receptores de Estrogênio/metabolismo , Antimetabólitos Antineoplásicos/uso terapêutico , Receptores de Progesterona/metabolismo , Pessoa de Meia-Idade , Idoso , AdultoAssuntos
Anticorpos Monoclonais Humanizados , Protocolos de Quimioterapia Combinada Antineoplásica , Camptotecina , Neoplasias de Mama Triplo Negativas , Humanos , Neoplasias de Mama Triplo Negativas/tratamento farmacológico , Neoplasias de Mama Triplo Negativas/patologia , Feminino , Anticorpos Monoclonais Humanizados/uso terapêutico , Anticorpos Monoclonais Humanizados/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Camptotecina/análogos & derivados , Camptotecina/uso terapêutico , Camptotecina/administração & dosagem , Pessoa de Meia-Idade , Antineoplásicos Imunológicos/uso terapêutico , ImunoconjugadosRESUMO
BACKGROUND: Male breast cancer (MBC) accounts for one percent of all breast cancers. Due to the lack of awareness and routine screening programs, most patients present with systemic disease at the time of diagnosis with low overall survival. OBJECTIVES: This study aims to investigate the prognostic factors of male breast cancer and its correlation with established prognostic parameters and patient outcomes. METHODS: Thirty-eight male breast cancer patients are identified from the MKA Breast Cancer Clinic database, and their corresponding clinical and pathological characteristics are obtained. Cut-off values of 1% and 10% are applied to further classify ER and PR results. RESULTS: Older men are more likely to develop MBC than younger men and are more likely to have spread to axillary lymph nodes. Invasive ductal carcinoma is a more common histologic type in MBC. All the tested patients have ER and PR positivity. Distant metastasis developed in 17/38 (44.7%) patients. Bone metastasis is seen commonly in metastatic MBC. CONCLUSIONS: According to our cohort, MBC is seen in older males, presents in later stages, and shows hormone receptor positivity and a tendency to bone involvement. MBC is a heterogenous but distinct biological entity requiring a specific clinical and pathological approach.
Assuntos
Neoplasias Ósseas , Neoplasias da Mama Masculina , Neoplasias da Mama , Carcinoma Ductal de Mama , Humanos , Masculino , Idoso , Neoplasias da Mama/patologia , Neoplasias da Mama Masculina/patologia , Prognóstico , Linfonodos/patologia , Carcinoma Ductal de Mama/patologia , Receptores de ProgesteronaAssuntos
Neoplasias da Mama , Carcinoma in Situ , Carcinoma Ductal de Mama , Carcinoma Intraductal não Infiltrante , Humanos , Feminino , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/etiologia , Carcinoma Intraductal não Infiltrante/patologia , Carcinoma Ductal de Mama/patologia , Carcinoma in Situ/patologiaAssuntos
Antineoplásicos , Neoplasias da Mama , Policetídeos de Poliéter , Humanos , Feminino , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Proteína C-Reativa/uso terapêutico , Interleucina-6 , Antineoplásicos/uso terapêutico , Furanos/efeitos adversos , Cetonas/efeitos adversosRESUMO
Objectives: This prospective study was planned to compare the predictive value of dynamic 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in locally advanced breast cancer patients (LABC) receiving neoadjuvant chemotherapy (NAC). Methods: Twenty seven patients with LABC [median age: 47, (26-66)] underwent a dynamic 18F-FDG PET study at baseline, and after 2-3 cycles of (NAC) were included (interim). Maximum standardized uptake value (SUVmax) values and SUV ratios for the 2nd, 5th, 10th, and 30th minutes and dynamic curve slope (SL) values and SL ratios were measured using 18F-FDG dynamic data. In addition, the values of SUVmean (2minSUVmean), SULpeak (2minSULpeak), metabolic volume (2minVol), and total lesion glycolysis (2minTLG) were measured for the first 2 min. Percent changes between baseline and interim studies were calculated and compared with the pathological results as the pathological complete response (PCR) or the pathological non-complete response (non-PCR). Receiver operating characteristic curves were obtained to calculate the area under the curve to predict PCR. Optimal threshold values were calculated to discriminate between PCR and non-PCR groups. Results: Baseline study SUV 30 (p=0.044), SUV 30/2 (p=0.041), SUV 30/5 (p=0.049), SUV 30/10 (p=0.021), SL 30/2 (p=0.029) and SL 30/5 (p=0.027) values were statistically significant different between PCR and non-PCR groups. The percentage changes of 2minVol between PCR and non-PCR groups were statistically significant. For the threshold value of -67.6% change in 2minVol, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 87.2%, 77.8%, 63.6%, 93.3%, and 80.7%, respectively (area under the curve: 0.826, p=0.009). Conclusion: Semiquantitative parameters for dynamic 18F-FDG PET can predict PCR. % changes in 2minVol can identify non-responding patients better than other parameters.